top of page
Intellectual Property Services
The defining characteristic of the international research-based pharmaceutical industry is its commitment to innovative, but expensive, R&D investment, and the cornerstone of protecting this investment is via executing a robust intellectual property (IP) policy.
At TBS we understand the importance of IP policy and how it relates to ensuring that an asset is protected, compliant and fulfills its maximum Return on Investment (RoI). Whether you are an innovator seeking protection for a New Chemical Entity (NCE) or a generic/biosimilar manufacturer, we can help create a clear road map to launch your products.
IP Portfolio Management & Optimization
Value maximization: IP management of existing portfolios, including supporting R&D teams to identify evergreening or repurposing/reprofiling of current and future pipelines. i.e., 505b(2) products, i.e., new formulations, routes of delivery, chemical modifications (salts) and enantiomer switches.
Expertise with both small and large molecule products as well as MedTech, Diagnostic products
Review and clarifications for in-house teams when it comes to parallel “sui generis” rights in the pharmaceutical industry, i.e., data protection, market protection, Supplementary Protection Certificate (SPC) and Orphan designation
In conjunction with other commercial services input into due diligence and gap analysis activities to provide a “complete picture.”
Providing go/no decisions for New Product Development (NPD) teams when looking to develop pharmaceutical assets
Patent Drafting & Intelligence
Conducting Freedom to Operate (FTO) searches for in/out licensing deals
Patentability evaluations that highlight patent infringement
Patent analytics services for the fund raising community (VC/PE/Angel/Hedge Fund), i.e., helping investors understand the current/future life science IP landscape to identify "hot" areas in the healthcare space
Developing patentability arguments for/against
Let's Work Together
bottom of page